Affiliation:
1. Michigan Technological University
Abstract
Abstract
When it is in the template RNA, the naturally occurring m1A epitranscriptomic RNA modification was recently reported to be able to stop the RNA polymerization reaction catalyzed by the RNA dependent RNA polymerase (RdRp) of SARS-CoV-2. In this report, we report that m1A via its triphosphate form (m1ATP) can be incorporated into RNA by the same RdRp. These two findings point a new direction for antiviral drug development based on m1A for combatting COVID-19. More broadly, it is possible that the large pool of epigenetic RNA as well as DNA modifications could serve as a treasury for drug discovery aimed at combating various infectious and other diseases.
Funder
National Institutes of Health
National Science Foundation
Publisher
Research Square Platform LLC
Reference20 articles.
1. Systematic structure guided clustering of chemical lead compounds targeting RdRp of SARS-CoV-2;Alsulimani A;Minerva Biotechnology and Biomolecular Research,2022
2. J. RNA-dependent RNA polymerase of SARS-CoV-2 as a therapeutic target;Wang YY;Journal of Medical Virology,2021
3. SARS-CoV-2 RdRp inhibitors selected from a cell-based SARS-CoV-2 RdRp activity assay system;Min JS;Biomedicines,2021
4. Overview of the global vaccine ecosystem;Moradpour J;Expert Review of Vaccines,2023
5. Fox, N.; Adams, P.; Grainger, D.; Herz, J.; Austin, C. The value of vaccines: A tale of two parts. Vaccines (Basel) 2022, 10 (12), 2057. doi:10.3390/vaccines10122057